JP2005526046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526046A5 JP2005526046A5 JP2003570814A JP2003570814A JP2005526046A5 JP 2005526046 A5 JP2005526046 A5 JP 2005526046A5 JP 2003570814 A JP2003570814 A JP 2003570814A JP 2003570814 A JP2003570814 A JP 2003570814A JP 2005526046 A5 JP2005526046 A5 JP 2005526046A5
- Authority
- JP
- Japan
- Prior art keywords
- location
- group
- alkyl
- oxygen
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 methylene, monochloromethylene Chemical group 0.000 claims description 52
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 10
- YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 claims description 9
- 239000001226 triphosphate Substances 0.000 claims description 9
- 235000011178 triphosphate Nutrition 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- WWMWAMFHUSTZTA-KQYNXXCUSA-N adenosine 5'-(pentahydrogen tetraphosphate) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O WWMWAMFHUSTZTA-KQYNXXCUSA-N 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 239000001177 diphosphate Substances 0.000 claims description 5
- 235000011180 diphosphates Nutrition 0.000 claims description 5
- UKYWNQGJLGDZPP-UHFFFAOYSA-N 4a-(3-methoxyphenyl)-1H-pyrrolo[2,3-d]pyrimidin-2-one Chemical compound COC=1C=C(C=CC=1)C12C(=NC(N=C1)=O)NC=C2 UKYWNQGJLGDZPP-UHFFFAOYSA-N 0.000 claims description 4
- WWMWAMFHUSTZTA-UHFFFAOYSA-N Adenosine tetraphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O WWMWAMFHUSTZTA-UHFFFAOYSA-N 0.000 claims description 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 4
- 229940045145 uridine Drugs 0.000 claims description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- UIWZRQJQAAXUIL-UHFFFAOYSA-N C(C)OC1=CC=C(C=C1)N(CC(=O)O)CP(=O)(O)O Chemical compound C(C)OC1=CC=C(C=C1)N(CC(=O)O)CP(=O)(O)O UIWZRQJQAAXUIL-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 17
- 239000001301 oxygen Substances 0.000 claims 17
- 230000002207 retinal effect Effects 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 125000004104 aryloxy group Chemical group 0.000 claims 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims 8
- 150000002243 furanoses Chemical group 0.000 claims 7
- 208000026062 Tissue disease Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010036790 Productive cough Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 239000000499 gel Substances 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000024794 sputum Diseases 0.000 claims 3
- 210000003802 sputum Anatomy 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 2
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000005110 aryl thio group Chemical group 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 230000001886 ciliary effect Effects 0.000 claims 2
- PFBUKDPBVNJDEW-UHFFFAOYSA-N dichlorocarbene Chemical group Cl[C]Cl PFBUKDPBVNJDEW-UHFFFAOYSA-N 0.000 claims 2
- LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 claims 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 239000006194 liquid suspension Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 230000000007 visual effect Effects 0.000 claims 2
- VMTDDSWHQZERET-UHFFFAOYSA-N 4a-(3-methylphenyl)-1H-pyrrolo[2,3-d]pyrimidin-2-one Chemical compound CC=1C=C(C=CC=1)C12C(=NC(N=C1)=O)NC=C2 VMTDDSWHQZERET-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010011033 Corneal oedema Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 201000010183 Papilledema Diseases 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 206010038886 Retinal oedema Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000036866 Vitreoretinopathy Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- KFCUPNHUPHDVJC-UHFFFAOYSA-N bromine azide Chemical compound BrN=[N+]=[N-] KFCUPNHUPHDVJC-UHFFFAOYSA-N 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 201000004778 corneal edema Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 150000005676 cyclic carbonates Chemical class 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000004986 diarylamino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000007717 exclusion Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 150000003949 imides Chemical class 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000008832 photodamage Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000010349 pulsation Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 201000011195 retinal edema Diseases 0.000 claims 1
- 150000008223 ribosides Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000007970 thio esters Chemical class 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 239000012038 nucleophile Substances 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- AZSFNUJOCKMOGB-UHFFFAOYSA-K cyclotriphosphate(3-) Chemical compound [O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 AZSFNUJOCKMOGB-UHFFFAOYSA-K 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- YTFJQDNGSQJFNA-UHFFFAOYSA-L benzyl phosphate Chemical compound [O-]P([O-])(=O)OCC1=CC=CC=C1 YTFJQDNGSQJFNA-UHFFFAOYSA-L 0.000 description 1
- MFGWMAAZYZSWMY-UHFFFAOYSA-N beta-naphthyl carbinol Natural products C1=CC=CC2=CC(CO)=CC=C21 MFGWMAAZYZSWMY-UHFFFAOYSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- VSSAZBXXNIABDN-UHFFFAOYSA-N cyclohexylmethanol Chemical compound OCC1CCCCC1 VSSAZBXXNIABDN-UHFFFAOYSA-N 0.000 description 1
- 229940042400 direct acting antivirals phosphonic acid derivative Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- OANJUVKBVUGTJK-UHFFFAOYSA-N naphthalen-2-ylmethyl dihydrogen phosphate Chemical compound C1=CC=CC2=CC(COP(O)(=O)O)=CC=C21 OANJUVKBVUGTJK-UHFFFAOYSA-N 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 150000003007 phosphonic acid derivatives Chemical class 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/082,998 US7115585B2 (en) | 2000-08-21 | 2002-02-27 | Compositions for treating epithelial and retinal tissue diseases |
| US10/082,998 | 2002-02-27 | ||
| PCT/US2003/006691 WO2003072067A2 (en) | 2002-02-27 | 2003-02-27 | Compositions and methods for treating epithelial and retinal tissue diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005526046A JP2005526046A (ja) | 2005-09-02 |
| JP2005526046A5 true JP2005526046A5 (enExample) | 2006-04-06 |
| JP4745610B2 JP4745610B2 (ja) | 2011-08-10 |
Family
ID=27765292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003570814A Expired - Fee Related JP4745610B2 (ja) | 2002-02-27 | 2003-02-27 | 上皮及び網膜組織疾患の治療のための組成物及び治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7115585B2 (enExample) |
| EP (2) | EP1545555A4 (enExample) |
| JP (1) | JP4745610B2 (enExample) |
| KR (1) | KR100990346B1 (enExample) |
| CN (1) | CN1671398A (enExample) |
| AR (1) | AR038612A1 (enExample) |
| AU (1) | AU2003223225B2 (enExample) |
| BR (1) | BR0307783A (enExample) |
| CA (1) | CA2477241C (enExample) |
| MX (1) | MXPA04008293A (enExample) |
| TW (1) | TW200408399A (enExample) |
| WO (1) | WO2003072067A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435724B2 (en) * | 2002-02-27 | 2008-10-14 | Inspire Pharmaceutical, Inc. | Degradation-resistant mononucleoside phosphate compounds |
| US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| WO2006071186A1 (en) * | 2004-12-27 | 2006-07-06 | Astrazeneca Ab | Use of gabab receptor agonists |
| WO2006105529A1 (en) * | 2005-03-30 | 2006-10-05 | Inspire Pharmaceuticals, Inc. | Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles |
| KR100870104B1 (ko) * | 2005-11-28 | 2008-11-26 | 주식회사 머젠스 | 안구건조증 치료 및 예방용 조성물 |
| EP2123285A1 (en) * | 2008-05-21 | 2009-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| US9221868B2 (en) * | 2010-12-01 | 2015-12-29 | Bar-Ilan University | Uridine di- or tri-phosphate derivatives and uses thereof |
| EP2669292B1 (en) | 2011-01-26 | 2017-03-29 | Beijing KBD Pharmaceuticals Co., Ltd. | Ribofuranosyl purine compounds for treating diseases associated with platelet aggregation |
| WO2014060941A2 (en) * | 2012-10-17 | 2014-04-24 | Mahesh Kandula | Compositions and methods of neuroprotective agents for the treatment of neurological and neurodegenerative diseases |
| EP3978003A1 (en) | 2016-02-18 | 2022-04-06 | Invirsa, Inc. | Medical use of 5'-adenosine diphosphate ribose (adpr) |
| CN111201040A (zh) * | 2017-05-10 | 2020-05-26 | 灰色视觉公司 | 用于医学疗法的缓释微粒及其悬浮液 |
| AU2019216531A1 (en) | 2018-02-02 | 2020-09-24 | Maverix Oncology, Inc. | Small molecule drug conjugates of gemcitabine monophosphate |
| WO2019191026A2 (en) | 2018-03-27 | 2019-10-03 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
| EP3849992A4 (en) | 2018-09-11 | 2022-06-29 | Risen (Suzhou) Pharma Tech Co., Ltd. | Cd73 inhibitors and pharmaceutical uses thereof |
| US11530234B2 (en) | 2018-09-11 | 2022-12-20 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 inhibitors and pharmaceutical uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3321462A (en) * | 1963-07-15 | 1967-05-23 | Syntex Corp | Process for the preparation of nucleoside polyphosphates |
| US3324110A (en) * | 1965-02-05 | 1967-06-06 | Schering Corp | Method of phosphorylation and novel intermediates produced thereby |
| JPS509872B1 (enExample) * | 1969-12-22 | 1975-04-16 | ||
| JPS5427581A (en) * | 1977-08-02 | 1979-03-01 | Mitsubishi Chem Ind Ltd | P1-s-phenylthiop2-nucleoside 5'-pyrophosphates and their preparation |
| JPS5427582A (en) * | 1977-08-02 | 1979-03-01 | Mitsubishi Chem Ind Ltd | Preparation of dinucleoside triphosphate |
| US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
| US4710566A (en) * | 1984-12-27 | 1987-12-01 | Yale University | Purification of the messenger RNA cap-binding protein |
| GB8529684D0 (en) * | 1985-12-02 | 1986-01-08 | Medical Res Council | Photo-labile protecting agents |
| JPS62265299A (ja) * | 1985-12-18 | 1987-11-18 | Senjiyu Seiyaku Kk | α―トコフェロールとウリジンとのリン酸ジエステル，そのハロゲン置換体もしくはこれらの塩およびそれらの製造法 |
| WO1988009171A1 (en) * | 1987-05-19 | 1988-12-01 | Baylor College Of Medicine | Phosphoethanolamine for treatment of alzheimer's disease |
| DE69204717T2 (de) | 1991-04-06 | 1996-04-25 | Astra Pharmaceuticals Limited, Kings Langley, Herts | ATP-Analogen. |
| US5654285A (en) * | 1991-04-06 | 1997-08-05 | Astra Pharmaceuticals Limited | ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation |
| US5292498A (en) * | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
| SK281309B6 (sk) * | 1993-02-10 | 2001-02-12 | Astra Pharmaceuticals Limited | N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov |
| US5444541A (en) * | 1994-02-16 | 1995-08-22 | Eastern Washington University | Methods for photoacoustically analyzing chemicals and chemical reactions using photoactive particle-emitting compounds |
| US5536822A (en) * | 1994-03-09 | 1996-07-16 | University Of Virginia Alumni Patents Foundation | γ-phosphate linked adenosine 5' triphosphate sepharose |
| US5635160A (en) * | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
| HU221880B1 (hu) * | 1995-07-11 | 2003-02-28 | Astrazeneca Ab, | Vérlemezke-aggregáció inhibitorok, ezeket tartalmazó gyógyszerkészítmények és előállításuk |
| US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| US5981507A (en) * | 1995-12-14 | 1999-11-09 | Advanced Magnetics, Inc. | Polymeric carriers linked to nucleotide analogues via a phosphoramide bond |
| US5837861A (en) * | 1997-02-10 | 1998-11-17 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
| US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| US6319908B1 (en) * | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
| WO1998018430A2 (en) * | 1996-10-30 | 1998-05-07 | The University Of North Carolina At Chapel Hill | P2y receptor antagonists |
| ATE213245T1 (de) | 1996-12-20 | 2002-02-15 | Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente | |
| WO1998034942A2 (en) * | 1997-02-06 | 1998-08-13 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use |
| SE9701219D0 (sv) * | 1997-04-04 | 1997-04-04 | Astra Pharma Prod | New compounds |
| SE9702774D0 (sv) * | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| WO1999061012A2 (en) * | 1998-05-22 | 1999-12-02 | Inspire Pharmaceuticals, Inc. | Therapeutic dinucleotide and derivatives |
| AU4125599A (en) * | 1998-06-08 | 1999-12-30 | Anette Henneberry | Cloning of human choline / ethanolaminephospho - transferases; synthesis of phosphatidyl - choline, phosphatidyle - thanolamine, and platelet activating factor |
| SE9804175D0 (sv) | 1998-12-02 | 1998-12-02 | Astra Pharma Prod | New assay |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| SE9903290D0 (sv) | 1999-09-15 | 1999-09-15 | Astra Pharma Prod | Novel compounds |
| SE9904129D0 (sv) | 1999-11-15 | 1999-11-15 | Astra Pharma Prod | Novel compounds |
| US6399335B1 (en) * | 1999-11-16 | 2002-06-04 | Advanced Research And Technology Institute, Inc. | γ-phosphoester nucleoside triphosphates |
| SE9904377D0 (sv) | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
| US6864243B1 (en) * | 2000-05-12 | 2005-03-08 | Inspire Pharmaceuticals, Inc. | Method for treating retinal degeneration with purinergic receptor agonists |
| CA2328684A1 (en) * | 2000-12-15 | 2002-06-15 | Yahia Gawad | Photon-triggered luminescent assay |
-
2002
- 2002-02-27 US US10/082,998 patent/US7115585B2/en not_active Expired - Fee Related
-
2003
- 2003-02-27 AU AU2003223225A patent/AU2003223225B2/en not_active Ceased
- 2003-02-27 CA CA2477241A patent/CA2477241C/en not_active Expired - Fee Related
- 2003-02-27 AR ARP030100650A patent/AR038612A1/es unknown
- 2003-02-27 BR BR0307783-7A patent/BR0307783A/pt not_active IP Right Cessation
- 2003-02-27 EP EP03719355A patent/EP1545555A4/en not_active Withdrawn
- 2003-02-27 MX MXPA04008293A patent/MXPA04008293A/es active IP Right Grant
- 2003-02-27 JP JP2003570814A patent/JP4745610B2/ja not_active Expired - Fee Related
- 2003-02-27 EP EP13002486.2A patent/EP2647382A1/en not_active Withdrawn
- 2003-02-27 TW TW092104241A patent/TW200408399A/zh unknown
- 2003-02-27 WO PCT/US2003/006691 patent/WO2003072067A2/en not_active Ceased
- 2003-02-27 CN CNA038040085A patent/CN1671398A/zh active Pending
- 2003-02-27 KR KR1020047013318A patent/KR100990346B1/ko not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9156874B2 (en) | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs | |
| CN104640444B (zh) | 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药 | |
| JP3802057B2 (ja) | ヌクレオシド一リン酸の新規の脂質エステル及び免疫抑制薬としてのその利用 | |
| KR101233824B1 (ko) | Ｈｉｖ 억제제 화합물인 포스포네이트 유사체 | |
| FI104176B (fi) | Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi | |
| ES2317912T3 (es) | Profarmacos 3'de 2'-deoxi-beta-l-nucleosidos. | |
| ES2928202T3 (es) | Compuestos químicos | |
| AU2004233989A1 (en) | Anti-cancer phosphonate analogs | |
| JP2013035841A (ja) | ホスホノ−ペント−２−エン−１−イルヌクレオシド及び類似体 | |
| AU2001266927A1 (en) | 3'-prodrugs of 2'-deoxy-beta-L-nucleosides | |
| JPH08501071A (ja) | １，５−アンヒドロヘキシトールヌクレオシド類似体および該類似体の医薬としての使用 | |
| JP2007238621A (ja) | 抗ウイルス性ホスホネート類似物 | |
| KR20090007569A (ko) | 항바이러스제로서의 2'-플루오로뉴클레오시드 포스포네이트 | |
| BR112020025132A2 (pt) | inibidores de ectonucleotidase e métodos de uso dos mesmos | |
| CA3153281A1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| KR100990346B1 (ko) | 상피 및 망막 조직 질환 치료용 조성물 및 방법 | |
| CN101511185A (zh) | 唑类核苷和作为rna和dna病毒聚合酶抑制剂的用途 | |
| JP2002531573A (ja) | グリセリルヌクレオチド、それらの製造法および使用 | |
| KR20060015542A (ko) | 산업 규모의 뉴클레오시드 합성 | |
| CN1780643B (zh) | 抗病毒的膦酸酯类似物 | |
| WO2015177351A1 (en) | Phosphonate nucleosides useful in the treatment of viral diseases | |
| JPH08512040A (ja) | デオキシヌクレオシドのリポヌクレオチド、それらの製造方法および抗ウイルス薬としてのそれらの用途 | |
| JPWO2003068796A1 (ja) | ４’−ｃ−シアノ−２’−デオキシプリンヌクレオシド |